RIPA-56 is a highly potent, metabolically stable and selective inhibitor of RIP1 (RIPK1).

 

Brand: BCM

 

Target: RIP kinase

 

Signaling Pathways: Apoptosis; NF-κB

 

In Vivo: In the SIRS mice disease model, RIPA-56?efficiently reduced tumor necrosis factor alpha (TNFα)-induced mortality and multi-organ damage.?Compared to known RIP1 inhibitors, RIPA-56?is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model?studies.

 

Boiling Point: 346.0±35.0 °C(Predicted)

 

pKa: 9.42±0.50(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: CCC(C)(C)C(=O)N(CC1=CC=CC=C1)O  

 

InChIKey: AVYVHIKSFXVDBG-UHFFFAOYSA-N  

 

InChI: InChI=1S/C13H19NO2/c1-4-13(2,3)12(15)14(16)10-11-8-6-5-7-9-11/h5-9,16H,4,10H2,1-3H3

 

Attribute
[CAS No.]	1956370-21-0
[Formula]	C13H19NO2
[Molecular]	221.29546
[Chem Name]	N-benzyl-N-hydroxy-2,2-dimethylbutanamide
[Storage]	Sealed in dry, 2-8°C
[Synonym]	A1-28956; RIPA-56
[MDL No.]	MFCD30738006
[Form]	White solid

Goods Tag